Recital 6, Regulation (EU) 2021/756

In forcesince 24 Mar 2021

In order to ensure the continued effectiveness of authorised COVID-19 vaccines, it may be necessary to modify them in ways that involve changing their composition so as to protect against new or multiple variant strains in the context of the pandemic or otherwise. Such changes, which include the replacement or addition of a serotype, strain or antigen or a combination of serotypes, strains or antigens, should be considered as variations to the marketing authorisation in accordance with Commission Regulation (EC) No 1234/2008 [Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination of variations to the terms of marketing authorisations for medicinal products for human use and veterinary medicinal products (OJ L 334, 12.12.2008, p. 7).]. Some vaccines are based on nucleic acid technology to produce an immune response. Modifications of those vaccines may include changes to the coding sequence.